Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in ICVTS w1x.
Clinical scenario
A 72-year-old male is listed for isolated aortic valve replacement (AVR) for severe aortic stenosis (AS). He tells you that he has heard that he might require a pacemaker after his operation. He asks you the likelihood of this and if there is anything that can be done to minimise this risk. You feel unable to quote him accurate estimates and decide to investigate further.
Three-part question
In wpatients undergoing aortic valve replacementx what wpreoperative, perioperative and postoperative factorsx predict the wrequirement for permanent pacemaker implantationx? *Corresponding author. Tel.: q44 191 2448983; fax: q44 191 2231139 . E-mail address: igmatthews@doctors.org.uk (I.G. Matthews).
Search strategy
An English language literature review was performed on MEDLINE using the Ovid interface from 1980 to April 2010:
wheart valve prosthesis implantationyOR heart valve prosthesisyOR prosthesis implantationyOR aortic valveyOR aortic valve surgeryyOR aortic valve implantation.mpx AND wpacemaker, artificialyOR cardiac pacing, artificialyOR heart blockyOR postoperative complicationsyOR permanent pacemaker.mpyOR permanent pacemaker implantation.mpx.
EMBASE was searched using the Ovid interface from 1980 to April 2010:
wheart valve replacementyOR heart valve surgeryyOR heart valve prosthesisyOR aorta valveyOR aortic valve implantation.mpx AND wpacemakeryOR artificial heart pacemakeryOR postoperative complicationyOR heart blockyOR permanent pacemaker.mpyOR permanent pacemaker implantation.mpx.
Additionally, the CINAHL wCumulative Index to Nursing and Allied Health Literaturex database and the Cochrane Database for Systematic Reviews and Central Register of Controlled Trials were searched using the above terms. All citations and abstracts were reviewed and reference lists of articles found through these strategies were reviewed for further relevant articles. AVR, aortic valve replacement; PPM, permanent pacemaker; AS, aortic stenosis; AR, aortic regurgitation; AV, atrioventricular; AVB, atrioventricular block; MVR, mitral valve replacement; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; PHT, pulmonary hypertension; MI, myocardial infarction; EF, ejection fraction; LBBB, left bundle branch block; RBBB, right bundle branch block; LV, left ventricle; NS, not significant.
Search outcome
A total of 705 papers were found using this search strategy. No randomised controlled trials, meta-analyses or registries were identified. Seven single-centre retrospective observational case series represent the best evidence on the topic and are summarised in Table 1 w2-8x.
Discussion
All seven studies are retrospective single-centre observational case series, inclusive of 2557 patients from Asia, Europe and North America. There is no randomised controlled data in this field. The incidence of permanent pacemaker (PPM) implantation postAVR varied from 3.0% to 11.8% (mean 7.0%, median 7.2%). In each study, multivariate logistic regression analysis was undertaken to identify preoperative, perioperative and postoperative predictors of PPM implantation.
Preoperative predictors
The most consistently identified preoperative predictor for PPM insertion was evidence of preoperative conducting system disease including left bundle branch block (LBBB) and right bundle branch block (RBBB), first degree atrioventricular block (AVB) and left anterior hemiblock.
Additional, preoperative predictors identified in more than one series were preoperative myocardial infarction (MI) w3, 4x and aortic regurgitation (AR) as the primary valvular pathology w3, 6x. It is postulated that annular ectasia associated with AR imposes mechanical stretch on the nearby AV node and his bundle that is further damaged during surgery w3x. Fibrous endocardial thickening of the ventricular septum and subsequent impingement of the underlying conducting tissue has also been implicated w6x. Nardi et al. w8x found that those with greater septal hypertrophy and greater end-systolic diameter, indirect evidence of more severe valvular disease, were more likely to require PPM implantation. Similarly, several other indirect indices of more severe valvular disease were identified as predictors: ejection fraction (EF) -35% w4x, pulmonary hypertension (PHT) w3x, hypertension and aortic annular calcification w5x. Lastly, female sex and a bicuspid aortic valve were identified as preoperative predictors w5x.
Perioperative pedictors
Only two series examined a specific surgical techniquey strategy. Totaro et al. w2x found that a continuous suture technique to secure the new prosthesis versus an interrupted suture technique resulted in a greater need for PPM implantation (17.5% vs. 2.2%, P-0.01). The continuous suture technique was associated with longer cardiopulmonary bypass (CPB) time (73"24 min vs. 60"24 min, P-0.01). Elahi and Usmaan w4x identified that a stentless aortic prosthesis for AS was associated with a higher rate of PPM implantation in comparison with a stented prosthesis (18.0% vs. 9.1%, P-0.05). The CPB time was longer in the stentless valve group (107.5"20.7 min vs. 81.3"13.4 min, P-0.05). Whether, it is the surgical techniques in isolation or their association with longer CPB times that is the important factor is uncertain. However, a longer CPB time, independent of surgical technique was identified as a predictor of PPM implantation w5x.
Other perioperative factors identified as predictors include smaller valvular prosthesis (F21 mm) w4x and concurrent mitral and AVR w7x. Multi-valve surgery is recognised as increasing the risk of PPM implantation in much larger observational series incorporating all types of cardiac surgery w9, 10x.
Postoperative predictors
Postoperative predictive factors are the least defined in the series. Only a postoperative cardiac arrest w7x and electrolyte disturbance w3x were identified as predictors of PPM implantation.
The period of time postAVR to allow AVB to persist prior to implanting a PPM varied in the studies, ranging from four to 10 days. Current European Society of Cardiology (ESC) guidelines w11x recommend a PPM in those with persistent postoperative heart block lasting for seven days postsurgery whilst the American Heart AssociationyAmerican College of CardiologyyHeart Rhythm Society guidelines w12x leave the decision at the discretion of the physician. Four studies report the mean or median time to implant postAVR, which ranged from 6.1 to 13 days w3, 6-8x. In larger observational series incorporating all types of cardiac surgery, the mean time to PPM implant ranged from 8.4 to 13 days w10, 13-15x. The period of seven days advocated by ESC guidance is within the range of all the previously mentioned studies.
Clinical bottom line
The most consistent preoperative predictor of PPM requirement postAVR is evidence of pre-existing conducting system disease. AR as the dominant valvular pathology and prior MI also confer a greater risk of PPM implantation. A longer CPB time was a consistent perioperative predictor whilst no consistent postoperative predictors have been identified. The time to PPM implant postAVR ranged from 6.1 to 13 days in the four studies that reported it. Current ESC guidelines recommend a period of seven days of persistent AVB postsurgery prior to PPM implantation.
